Alzheimer Disease/Dementia

>

Latest News

Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease / Image credit: ©LIGHTFIELD STUDIOS/AdobeStock
Donanemab Showed Sustained Cognitive Benefit Over 3 Years in Early Alzheimer Disease

July 30th 2025

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

Alzheimer's Association Releases First Clinical Guideline on Use of Blood-Based Biomarker Tests / image credit ©ryandi/stock.adobe.com
Alzheimer's Association Releases First Clinical Guideline on Use of Blood-Based Biomarker Tests

July 30th 2025

Remote Cognitive Screening Platform Expands Access to Early Detection / Image credit: ©Visualmind/AdobeStock
Remote Cognitive Screening Platform Expands Access to Early Detection

July 29th 2025

Trontinemab Phase 3 Alzheimer Trials to Launch Following Promising Amyloid Clearance Data
Trontinemab Phase 3 Alzheimer Trials to Launch Following Promising Amyloid Clearance Data

July 28th 2025

EMA Advisory Group Issues Positive Opinion on Lilly's Donanemab for Treatment of Early Alzheimer Disease / image credit ©namphon/stock.adobe.com via AI
EMA Advisory Group Issues Positive Opinion on Lilly's Donanemab for Treatment of Early Alzheimer Disease

July 25th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.